



# DIVA Investor Conference

**Dec 8, 2025**

**DIVA** Labs.

# Participants



Vice Chairman & CEO

Gene Chen



GM

Yvonne Liu



Admin VP & Spokesman

Michael Mai



Finance Senior Manager

Angel Chiang

# Agenda

## 一. Company Profile

Admin VP &  
Spokesman

Michael Mai

## 二. 2025 Q1-Q3 Financial Results

## 三. Business Update and Outlook

GM

Yvonne Liu

## 四. Q&A

Vice Chairman &  
CEO

Gene Chen

# Safe Harbor Notice

We have made forward-looking statements in the presentation. Our forward-looking statements contain information regarding, among other things, our financial conditions, future expansion plans and business strategies. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that these expectations and projections are reasonable, such forward-looking statements are inherently subject to risks, uncertainties, and assumptions about us.

We undertake no obligation to publicly update or revise any forward-looking statements whether as a result of new information, future events or otherwise. In light of these risks, uncertainties and assumptions, the forward-looking events might not occur and our actual results could differ materially from those anticipated in these forward-looking statements.



## — .Company Profile

Admin VP & Spokesman Michael Mai

# DIVA Labs.

Focused on providing high quality precision displays to meet the product requirements of global OEM and ODM customers

**Year Established**      **1995**

**IPO Year**                      **2013**  
(Ticker 4153)

**Capital (NTD)**              **587M**

**No. of Employees**      **145+**

## Global Presence

**Manufacturing Sites : Taiwan**

**Sales Offices : 3 Locations Worldwide**

**R&D : Taiwan**

**Revenue Breakdown by Geography :**

	2023	2024	2025
Americas	37%	46%	44%
Europe	44%	38%	37%
Taiwan	6%	4%	3%
Others	13%	12%	16%

**2025 Q1-Q3 Revenue**

**NTD\$ 639M ( USD\$ 20.5M )**

**2024 Revenue**

**NTD\$ 862M ( USD\$26.9M )**



## **二. 2025 Q1-Q3 Financial Results**

Admin VP & Spokesman Michael Mai

# 2025 Q1-Q3 Highlights

01

**Revenue for the first three quarters was flat YoY.**

+6.5% for medical, -6.1% for industrial.

02

**Operating income and net income attributable to the parent company YoY in the first three quarters**

- Operating income -14%, and net income attributable to the parent company -14%.

# Consolidated Statement of Comprehensive Income(Quarterly)

Unit : NT\$Million

	2025 Q3		2024 Q3		YoY		2025 Q2		QoQ	
	amt	g%								
Net Sales	197	100%	194	100%	3	2%	235	100%	(38)	-16%
Cost of Goods Sold	(145)		(135)		(11)		(163)		18	
Gross Margin	52	26%	59	30%	(7)	-12%	72	30%	(20)	-28%
Operating Expenses	(43)	-22%	(39)	-20%	(4)		(40)	-17%	(3)	
Operating Income	8	4%	20	10%	(11)	-58%	31	13%	(23)	-74%
Net non-operating Income	4		0		4		(5)		10	
Profit(Loss) before Tax	13	6%	20	10%	(7)	-36%	26	11%	(13)	-51%
Net Income	10	5%	15	8%	(5)	-33%	26	11%	(16)	-61%
Net income attributable to DIVA	10	5%	15	8%	(5)	-33%	26	11%	(16)	-61%
EPS (NT\$) (a)	\$0.17		\$0.26		-\$0.09		\$0.44		-\$0.27	

(a) EPS was calculated based on total weighted-averaged outstanding shares

# Consolidated Statement of Comprehensive Income (YTD)

Unit : NT\$Million


	2025 Q3		2024 Q3		YoY	
	amt	g%	amt	g%	amt	g%
Net Sales	639	100%	639	100%	0	0%
Cost of Goods Sold	(448)		(447)		(1)	
Gross Margin	191	30%	193	30%	(1)	-1%
Operating Expenses	(122)	-19%	(111)	-17%	(10)	
Operating Income	70	11%	81	13%	(12)	-14%
Net non-operating Income	2		3		(1)	
Profit(Loss) before Tax	71	11%	84	13%	(13)	-15%
Net Income	61	10%	70	11%	(10)	-14%
Net income attributable to DIVA	61	10%	70	11%	(10)	-14%
EPS (NT\$) (a)	\$1.04		\$1.20		-\$0.16	

(a) EPS was calculated based on total weighted-averaged outstanding shares


# Revenue and Operating Income

Unit : NT\$ Million

Unit : NT\$ Million



Revenue




Operating Income


# Consolidated Balance Sheet Highlights

Unit : NT\$ Million	2025.09.30		2025.06.30		QoQ		2024.09.30		YoY	
	amt	g%	amt	g%	amt	g%	amt	g%	amt	g%
Cash and cash equivalents	487	37%	643	46%	-156	-24%	546	44%	-59	-11%
Accounts receivable	290	22%	262	19%	28	11%	233	19%	57	24%
Inventories	227	17%	192	14%	35	18%	175	14%	52	29%
<b>Total Assets</b>	<b>1,314</b>	<b>100%</b>	<b>1,407</b>	<b>100%</b>	<b>-93</b>	<b>-7%</b>	<b>1,251</b>	<b>100%</b>	<b>63</b>	<b>5%</b>
Accounts payable	81	6%	72	5%	9	12%	66	5%	15	22%
Other payables	177	13%	281	20%	-104	-37%	99	8%	77	78%
<b>Total Liabilities</b>	<b>316</b>	<b>24%</b>	<b>422</b>	<b>30%</b>	<b>-107</b>	<b>-25%</b>	<b>219</b>	<b>18%</b>	<b>96</b>	<b>44%</b>
<b>Total Equity</b>	<b>998</b>	<b>76%</b>	<b>985</b>	<b>70%</b>	<b>13</b>	<b>1%</b>	<b>1,032</b>	<b>82%</b>	<b>-34</b>	<b>-3%</b>


# Consolidated revenue - by product application




# Consolidated revenue - by sales area



# Consolidated revenue - by customer segment



# Consolidated revenue - by revenue concentration





## Ξ. Business Update and Outlook

GM Yvonne Liu

# **DIVA's Strategy**

## **Optimization of existing customer operations**

Close to the needs of customers, and jointly develop future models

## **Expanding the market share of medical display**

Efforts to develop ODM market for medical display products

## **Lean manufacturing and R&D technology with synergy**

Group manufacturing strengths and established development technology capabilities

## **Provide total solutions**

Solve customers' problems in various situations of medical display use

**Major Pillars**

# 2026 Outlook

## **FX Rate / Exchange Rate Sensitivity**

- 2025 Q3 Avg. FX Rate: 29.6 NTD/USD; Gross Margin: 26%.
- Sensitivity: A 1% depreciation in USD decreases Gross Margin by approx. 0.4%.



## **Contribution from New Models**

- Large-format Medical Displays: Revenue growth of 80%.
- Ultrasound OLED Models: Shipments are ramping up steadily.



## **Standard Product Development & Market Entry**

- Medical HMI (21.5", 23.8") & 15.6" Type-C
- 32" Mini LED Display
- Surgical Displays FHD/4K (43", 55", 65")



## 四. Q&A



**Thank you**